DrugCentral: online drug compendium
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
DrugCentral (http://drugcentral.org) is an open-access online drug compendium. DrugCentral integrates structure, bioactivity, regulatory, pharmacologic actions and indications for active pharmaceutical ingredients approved by FDA and other regulatory agencies. Monitoring of regulatory agencies for new drugs approvals ensures the resource is up-to-date. DrugCentral integrates content for active ingredients with pharmaceutical formulations, indexing drugs and drug label annotations, complementing similar resources available online. Its complementarity with other online resources is facilitated by cross referencing to external resources. At the molecular level, DrugCentral bridges drug-target interactions with pharmacological action and indications. The integration with FDA drug labels enables text mining applications for drug adverse events and clinical trial information. Chemical structure overlap between DrugCentral and five online drug resources, and the overlap between DrugCentral FDA-approved drugs and their presence in four different chemical collections, are discussed. DrugCentral can be accessed via the web application or downloaded in relational database format.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There are 217 drugs annotated in DrugCentral10 as acting through 125 (T) ion channels for the MoA9.”
From Unexplored therapeutic opportunities in the human genome (2018) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Chemical structures were manually assigned to 140 of the latest veterinary drugs, and molecular descriptors and structure depictions were computed per DrugCentral workflow (1).”
From DrugCentral 2023 extends human clinical data and integrates veterinary drugs (2023) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“DrugCentral has been a public digital database aggregating drug information since 2016 (1).”
From DrugCentral 2023 extends human clinical data and integrates veterinary drugs (2023) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
KEGG for integration and interpretation of large-scale molecular data sets
Kanehisa, M., Goto, S., Sato, Y., Furumichi, M., & Tanabe, M. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr988 · Cited by 4,848 · cited 2×
“The following resources matched our above inclusion criteria: the ChEMBL database (1), the Guide to Pharmacology (2) and KEGG Drug (3).”
BackgroundMethodThe unified medical language system (UMLS): integrating biomedical terminology
Bodenreider, O. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh061 · Cited by 4,356
A comprehensive map of molecular drug targets
Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T. I., et al. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.230 · Cited by 2,427 · cited 1×
“) to which the API or its active metabolite binds directly, to exert the therapeutic drug action (22).”
BackgroundSelf-citationDrugBank 4.0: shedding new light on drug metabolism
Law, V., Knox, C., Djoumbou, Y., Jewison, T., Guo, A. C., Liu, Y., Maciejewski, A., Arndt, D., Wilson, M., Neveu, V., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1068 · Cited by 1,993 · cited 10×
“The overlap matrix was computed for DrugCentral, in comparison with the following drugfocused resources: the NIH Center for Chemical Genomics (NCGC) pharmaceutical collection (11), DrugBank (12), the IDAAPM database (13), the phase 4 drugs subset from the ChEMBL 21 release (1) and the e-Drug3D database (14).”
MethodInfluentialThe ChEMBL bioactivity database: an update
Bento, A. P., Gaulton, A., Hersey, A., Bellis, L. J., Chambers, J., Davies, M., Krüger, F. A., Light, Y., Mak, L., McGlinchey, S., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1031 · Cited by 1,492 · cited 5×
“Mechanism of action annotations in DrugCentral are aggregated from several expert curated resources: ChEMBL database (1), Guide to Pharmacology (2), KEGG Drug (3), as well as manual curations extracted from drug labels and literature.”
BackgroundMethodInfluentialThe SIDER database of drugs and side effects
Kuhn, M., Letunic, I., Jensen, L. J., & Bork, P. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1075 · Cited by 1,451 · cited 3×
“Drug adverse events from FDA AERS database (https://open.fda.gov/) and SIDER (21) will be used to enhance the drug safety profile of existing drug reports.”
BackgroundSouthan, C., Sharman, J. L., Benson, H. E., Faccenda, E., Pawson, A. J., Alexander, S. P. H., Buneman, O. P., Davenport, A. P., McGrath, J. C., Peters, J. A., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1037 · Cited by 1,035 · cited 3×
“Quantitative bioactivity data are aggregated from multiple sources including: ChEMBLDb (1) (58.73% of the records); DrugMatrix (23) (15.95%); WOMBAT-PK (24) (13.9%); Guide to Pharmacology (2) (5.29%); PDSP (25) (3.41%); scientific literature (2.35%); and drug labels (0.36%), respectively.”
BackgroundMethodInfluentialCalculating log Poct from structures
Leo, A. J. (1993) · Chemical Reviews · doi:10.1021/cr00020a001 · Cited by 695
Dalby, A., Nourse, J. G., Hounshell, W. D., Gushurst, A. K. I., Grier, D. L., Leland, B. A., & Laufer, J. (1992) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci00007a012 · Cited by 642 · cited 1×
“A multistep manual curation and validation process was employed to collect, record and store correct chemical information for API molecular structures in the MDL (‘Molecular Design Limited’) MOL format (8).”
MethodProperty distribution of drug-related chemical databases*
Oprea, T. I. (2000) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1008130001697 · Cited by 628
Self-citationThe ChEBI reference database and ontology for biologically relevant chemistry: enhancements for 2013
Hastings, J., de Matos, P., Dekker, A., Ennis, M., Harsha, B., Kale, N., Muthukrishnan, V., Owen, G., Turner, S., Williams, M., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1146 · Cited by 591
Kibbe, W. A., Arze, C., Felix, V., Mitraka, E., Bolton, E., Fu, G., Mungall, C. J., Binder, J. X., Malone, J., Vasant, D., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1011 · Cited by 580 · cited 2×
“int/classifications/icd/en), and Disease-Ontology (26) concepts.”
InChI - the worldwide chemical structure identifier standard
Heller, S., McNaught, A., Stein, S., Tchekhovskoi, D., & Pletnev, I. (2013) · Journal of Cheminformatics · doi:10.1186/1758-2946-5-7 · Cited by 477 · cited 3×
“We performed chemical structure comparisons using InChI (10) strings generated from the MOL V2000 records, i.e. omitting the enhanced stereo option, with unique APIs from several drug-focused databases, after removing salt/solvent and invalid/duplicated structure records.”
MethodInfluentialHuang, R., Southall, N., Wang, Y., Yasgar, A., Shinn, P., Jadhav, A., Nguyen, D.-T., & Austin, C. P. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001862 · Cited by 401 · cited 1×
“The overlap matrix was computed for DrugCentral, in comparison with the following drugfocused resources: the NIH Center for Chemical Genomics (NCGC) pharmaceutical collection (11), DrugBank (12), the IDAAPM database (13), the phase 4 drugs subset from the ChEMBL 21 release (1) and the e-Drug3D database (14).”
MethodDrug repurposing from an academic perspective
Oprea, T. I., Bauman, J. E., Bologa, C. G., Buranda, T., Chigaev, A., Edwards, B. S., Jarvik, J. W., Gresham, H. D., Haynes, M. K., Hjelle, B., et al. (2011) · Drug Discovery Today: Therapeutic Strategies · doi:10.1016/j.ddstr.2011.10.002 · Cited by 364 · cited 1×
“Drugs withdrawn due to other than safety reasons will be flagged and annotated with indication/pharmacology/MoA to create a comprehensive list of drugs with potential for drug repurposing (28,29).”
BackgroundSelf-citationThe Multiplicity of Serotonin Receptors: Uselessly Diverse Molecules or an Embarrassment of Riches?
Roth, B. L., Lopez, E., Patel, S., & Kroeze, W. K. (2000) · The Neuroscientist · doi:10.1177/107385840000600408 · Cited by 358
Ganter, B., Tugendreich, S., Pearson, C. I., Ayanoglu, E., Baumhueter, S., Bostian, K. A., Brady, L., Browne, L. J., Calvin, J. T., Day, G.-J., et al. (2005) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2005.03.022 · Cited by 285 · cited 2×
“Quantitative bioactivity data are aggregated from multiple sources including: ChEMBLDb (1) (58.73% of the records); DrugMatrix (23) (15.95%); WOMBAT-PK (24) (13.9%); Guide to Pharmacology (2) (5.29%); PDSP (25) (3.41%); scientific literature (2.35%); and drug labels (0.36%), respectively.”
InfluentialSelf-citationDevelopment of the Logical Observation Identifier Names and Codes (LOINC) Vocabulary
Huff, S. M., Rocha, R. A., McDonald, C. J., De Moor, G. J. E., Fiers, T., Bidgood, W. D., Forrey, A. W., Francis, W. G., Tracy, W. R., Leavelle, D., et al. (1998) · Journal of the American Medical Informatics Association · doi:10.1136/jamia.1998.0050276 · Cited by 235
SuperTarget goes quantitative: update on drug-target interactions
Hecker, N., Ahmed, J., von Eichborn, J., Dunkel, M., Macha, K., Eckert, A., Gilson, M. K., Bourne, P. E., & Preissner, R. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr912 · Cited by 213 · cited 1×
“SuperTarget (20) contains biological activity profile annotations for drugs listed in SuperDrug and adverse events extracted from SIDER (21).”
Backgrounde-Drug3D: 3D structure collections dedicated to drug repurposing and fragment-based drug design
Pihan, E., Colliandre, L., Guichou, J.-F., & Douguet, D. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts186 · Cited by 142 · cited 2×
“The e-Drug3D database (14) contains 3D conformations for Drugs@FDA entries, and provides information on commercially available drug fragments to facilitate computational drug repurposing and fragment based drug design.”
Oprea, T. I., Nielsen, S. K., Ursu, O., Yang, J. J., Taboureau, O., Mathias, S. L., Kouskoumvekaki, I., Sklar, L. A., & Bologa, C. G. (2011) · Molecular Informatics · doi:10.1002/minf.201100023 · Cited by 114 · cited 1×
“However, they are available for download in the MDL SDF format, which can be used for cheminformatics-related activities such as virtual screening, computational drug repurposing (18), chemical library coverage comparison and similarity analyses, as well as other applications where accurate chemical structure informat…”
MethodSelf-citationComputational and Practical Aspects of Drug Repositioning
Oprea, T. I., & Overington, J. P. (2015) · ASSAY and Drug Development Technologies · doi:10.1089/adt.2015.29011.tiodrrr · Cited by 113 · cited 1×
“Drugs withdrawn due to other than safety reasons will be flagged and annotated with indication/pharmacology/MoA to create a comprehensive list of drugs with potential for drug repurposing (28,29).”
BackgroundSelf-citationWOMBAT and WOMBAT‐PK: Bioactivity Databases for Lead and Drug Discovery
Olah, M., Rad, R., Ostopovici, L., Bora, A., Hadaruga, N., Hadaruga, D., Moldovan, R., Fulias, A., Mractc, M., & Oprea, T. I. (2007) · Chemical Biology · doi:10.1002/9783527619375.ch13b · Cited by 100
Self-citationSuperDrug: a conformational drug database
Goede, A., Dunkel, M., Mester, N., Frömmel, C., & Preißner, R. (2005) · Computer applications in the biosciences · doi:10.1093/bioinformatics/bti295 · Cited by 76
Legehar, A., Xhaard, H., & Ghemtio, L. (2016) · Journal of Cheminformatics · doi:10.1186/s13321-016-0141-7 · Cited by 25
Medical Terminologies That Work: The Example of MeSH
Nelson, S. J. (2009) · International Symposium on Pervasive Systems, Algorithms and Networks (ISPAN) · doi:10.1109/i-span.2009.84 · Cited by 20
Self-citation(1978) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci60013a609 · Cited by 7
(2006) · PubMed
Cited by
A comprehensive map of molecular drug targets
Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T. I., et al. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.230 · Cited by 2,427
Self-citationHarding, S. D., Sharman, J. L., Faccenda, E., Southan, C., Pawson, A. J., Ireland, S., Gray, A. J. G., Bruce, L., Alexander, S. P. H., Anderton, S., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1121 · Cited by 1,646
“The same figure shows that in the case of both DrugBank (18) and DrugCentral (19) there are ∼5500 CIDs unique to just GtoPdb.”
BackgroundZhang, P., Zhang, D., Zhou, W., Wang, L., Wang, B., Zhang, T., & Li, S. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad518 · Cited by 675
“Thus, the network relationships also include those between compounds or natural products and their relevant molecular targets mined from databases such as HIT [36],TCMGeneDIT [37],DrugCentral [38] and DrugBank [39].”
BackgroundSystematic integration of biomedical knowledge prioritizes drugs for repurposing
Himmelstein, D. S., Lizee, A., Hessler, C., Brueggeman, L., Chen, S. L., Hadley, D., Green, A., Khankhanian, P., & Baranzini, S. E. (2017) · eLife · doi:10.7554/elife.26726 · Cited by 666
Li, Y. H., Yu, C. Y., Li, X. X., Zhang, P., Tang, J., Yang, Q., Fu, T., Zhang, X., Cui, X., Tu, G., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1076 · Cited by 523
“In particular, a number of freely accessible databases complementarily provide comprehensive information about the therapeutic targets with additional information about the clinical trial drugs (11–13), biomarkers (11), molecular activity data (11,13–15), drug-binding sites (16,17) and targetaffiliated biological path…”
Background
Metadata
- Authors
- Ursu, O., Holmes, J., Knockel, J., Bologa, C. G., Yang, J. J., Mathias, S. L., Nelson, S. J., & Oprea, T. I.
- Affiliations
- University of New Mexico (US)
- Corresponding author
- Oprea, Tudor I.
- ORCID
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-10-26
- Volume
- 45
- Issue
- D1
- Pages
- D932-D939
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- PMC
- PMC5210665
- OpenAlex
- W2539985226
- Cited by
- 323
- References
- 29
- Citations by year
- 2026: 23 · 2025: 39 · 2024: 34 · 2023: 39 · 2022: 26 · 2021: 31 · 2020: 45 · 2019: 40 · 2018: 27 · 2017: 17 · 2016: 2
- FWCI
- 26.37
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nucleic Acids Research (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- UNM’s Digital Repository (University of New Mexico) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- European Bioinformatics Institute
- National Institutes of Health
- U.S. Food and Drug Administration
- National Cancer Institute (U54CA189205, P30CA118100)
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Health Informatics › Biomedical Text Mining and Ontologies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- pharmacopoeia, active pharmaceutical ingredients, FDA-approved drugs, drug labels, drug-target interactions, pharmacological activity, drug indications, drug formulation, text mining, drug adverse events
- MeSH terms
- Drug Compounding, Drug Interactions, Drug Labeling, Pharmaceutical Preparations, Humans, United States, United States Food and Drug Administration, Drug Approval, Search Engine, Databases, Pharmaceutical, Drug-Related Side Effects and Adverse Reactions, Web Browser
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.